This announcement is a separate document:
シンバイオ製薬：注射剤ブリンシドフォビルによる第2a相臨床試験（ATHENA試験）における造血幹細胞移植後のサイトメガロウイルス感染症を対象とした臨床試験開始のお知らせ
SymBio Pharmaceuticals: Notice of commencement of clinical trials targeting cytomegalovirus infection after hematopoietic stem cell transplantation in a phase 2a clinical trial (ATHENA trial) with the injectable brincidofovir
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.